Basic biomaterials research threatened by industry liability fears, AAAS panelists say.
This article was originally published in The Gray Sheet
Executive Summary
BASIC BIOMATERIALS RESEARCH IS THREATENED BY INDUSTRY'S LIABILITY FEARS, academic panelists maintained Feb. 19 at the American Association for the Advancement of Science annual meeting in Atlanta. "The industrial withdrawal from" biomaterials research and development "will eventually give us reduced manpower in the United States," said panelist James Anderson, Case Western Reserve University, Cleveland. "It already has had a major impact on industrial-academic collaborations in which research is carried out."
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.